Abdulrouf Pallivalapila

Abdulrouf Pallivalapila

Auto-generated profile, based on publicly available information

Abdulrouf Pallivalapila

Hamad Medical Corporation, Doha, Qatar

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
DSDerek Stewart
Derek Stewart
TJTesnime Jebara
Tesnime Jebara
SCScott Cunningham
Scott Cunningham
AAAhmed Awaisu
Ahmed Awaisu
APAbdulrouf Pallivalapila
Abdulrouf Pallivalapila
Katie MacLureKatie MacLure
Katie MacLure
Many countries have implemented nonmedical prescribing (NMP) and many others are scoping prescribing practices with a view to developing NMP. This paper provides a future perspective on NMP in light of findings of an umbrella review of aspects of NMP. This is followed by coverage of the Scottish Government strategy of pharmacist prescribing and finally, consideration of two key challenges. The review identified seven systematic reviews of influences on prescribing decision-making, processes of prescribing, and barriers and facilitators to implementation. Decision making was reported as complex with many, and often conflicting, influences. Facilitators of NMP included perceived improved patient care and professional autonomy, while barriers included lack of defined roles and resource pressures. Three systematic reviews explored patient outcomes that were noted to be equivalent or better to physician prescribing. In particular, a Cochrane review of 46 studies of clinical, patient-reported, and resource-use outcomes of NMP compared with medical prescribing showed positive intervention-group effects. Despite positive findings, authors highlighted high bias, poor definition and description of ‘prescribing’ and the ‘prescribing process’ and difficulty in separating NMP effects from the contributions of other healthcare team members. While evidence of benefit and safety is essential to inform practice, for NMP to be implemented and sustained on a large scale, there needs to be clear commitment at the highest level. The approach being taken by the Scottish Government to pharmacist prescribing implementation may inform developments in other professions and countries. The vision is that by 2023, all pharmacists providing pharmaceutical care will be pharmacist-independent prescribers. There are, however, challenges to implementing NMP into working practice; two key challenges are the need for sustainable models of care and evaluation research. These challenges could be met by considering the theoretical basis for implementation, and robust and rigorous evaluation.

30 September 2022 in Medical Teacher
Verified
Journal Article
Open access
MAMuna Said Al-Ismail
Muna Said Al-Ismail
LNLina Naseralallah
Lina Naseralallah
THTarteel Ali Hussain
Tarteel Ali Hussain
DSDerek Stewart
Derek Stewart
DADania Alkhiyami
Dania Alkhiyami
ZNZachariah Nazar
Zachariah Nazar
A rigorous learning needs assessment (LNA) is a crucial initial step in the Continuing Professional Development (CPD) process. This scoping review aimed to collate, summarize, and categorize the re...

23 February 2007 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
DSDerek Stewart
Derek Stewart
ARAbdul Rouf
Abdul Rouf
ASAilsa Snaith
Ailsa Snaith
KEKathleen Elliott
Kathleen Elliott
PHPeter J. Helms
Peter J. Helms
JMJames S. McLay
James S. McLay
What is already known about this subject • There are increasing concerns about the safety and efficacy of paediatric off‐label medicines.• In the UK, each year 26% of children receive an off‐label prescription from their general practitioner.• The community pharmacist is the final and key professional in the chain, with the responsibility to ensure that medicines are both prescribed and dispensed appropriately. What this study adds • The majority of community pharmacists are aware of off‐label prescribing, but through work experience rather than undergraduate or postgraduate training or professional development.• Community pharmacists, like UK general practitioners, underestimate the levels of paediatric off‐label prescribing, and appear unclear as to the most common reasons for a prescription being off label.• Most community pharmacists stated that they should inform the prescriber that a medicine was off label; however, when given specific practical examples, less than half would actually appear to do so.• The majority of community pharmacists have been asked by the public to sell over‐the‐counter medicines for paediatric off‐label use.Aim: To identify community pharmacist experiences of, and attitudes towards paediatric off‐label prescribing.Methods: A prospective questionnaire‐based study, with a 21‐item questionnaire issued to 1500 randomly selected community pharmacies throughout the UK during 2005 on three separate occasions.Results: Four hundred and eighty‐two (32.1%) completed questionnaires were returned. Over 70% of respondents were familiar with the concept of off‐label prescribing, primarily through dispensing experience rather than education, although only 40% were aware of having dispensed a paediatric off‐label prescription within the previous month. The reasons given for a prescription being off label were younger age than recommended (84.6%, 297/351), primarily for antihistamines, analgesics and β2‐agonists, and higher (73.9%, 229/310) or lower than (41%, 103/258) recommended dose, primarily antibiotics and analgesics. Over 60% of respondents had been asked by the public to sell paediatric over‐the‐counter medicines, such as antihistamines, analgesics and steroid preparations for off‐label use. The majority of respondents used the British National Formulary or the Pack Insert rather than specialist formularies or guidelines as a source of specialist paediatric information. Although 78% of respondents believed they had a responsibility to inform the prescriber that a medicine was off label, only 66% believed that they had a similar responsibility to inform parents.Conclusion: The community pharmacists who responded to this questionnaire appear to be aware of and concerned by the issues which surround paediatric off‐label prescribing. Despite this, most gained relevant knowledge through work experience rather than undergraduate or postgraduate training or professional development.

SYsalma younes
salma younes
Muthanna SamaraMuthanna Samara
Muthanna Samara
RARana Al-Jurf
Rana Al-Jurf
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
SASawsan Al-Obaidly
Sawsan Al-Obaidly
Nader Al-DewikNader Al-Dewik
Nader Al-Dewik
Preterm birth (PTB) and early term birth (ETB) are associated with high risks of perinatal mortality and morbidity. While extreme to very PTBs have been extensively studied, studies on infants born at later stages of pregnancy, particularly late PTBs and ETBs, are lacking. In this study, we aimed to assess the incidence, risk factors, and feto-maternal outcomes of PTB and ETB births in Qatar. We examined 15,865 singleton live births using 12-month retrospective registry data from the PEARL-Peristat Study. PTB and ETB incidence rates were 8.8% and 33.7%, respectively. PTB and ETB in-hospital mortality rates were 16.9% and 0.2%, respectively. Advanced maternal age, pre-gestational diabetes mellitus (PGDM), assisted pregnancies, and preterm history independently predicted both PTB and ETB, whereas chromosomal and congenital abnormalities were found to be independent predictors of PTB but not ETB. All groups of PTB and ETB were significantly associated with low birth weight (LBW), large for gestational age (LGA) births, caesarean delivery, and neonatal intensive care unit (NICU)/or death of neonate in labor room (LR)/operation theatre (OT). On the other hand, all or some groups of PTB were significantly associated with small for gestational age (SGA) births, Apgar < 7 at 1 and 5 min and in-hospital mortality. The findings of this study may serve as a basis for taking better clinical decisions with accurate assessment of risk factors, complications, and predictions of PTB and ETB.

7 June 2013 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
WEWessam Elkassem
Wessam Elkassem
APAbdulrouf Pallivalapila
Abdulrouf Pallivalapila
MHMoza Al Hail
Moza Al Hail
LMLorna McHattie
Lorna McHattie
Lesley DiackLesley Diack
Lesley Diack
DSDerek Stewart
Derek Stewart

19 December 2017 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JMJames S. McLay
James S. McLay
NINaila Izzati
Naila Izzati
APAbdul R. Pallivalapila
Abdul R. Pallivalapila
ASAshalatha Shetty
Ashalatha Shetty
BPBinita Pande
Binita Pande
DSDerek Stewart
Derek Stewart
Pregnant women are routinely prescribed medicines while self-medicating with herbal natural products to treat predominantly pregnancy related conditions. The aim of this study was to assess the potential for herb-drug interactions (HDIs) in pregnant women and to explore possible herb-drug interactions and their potential clinical significance. A cross-sectional survey of women during early pregnancy or immediately postpartum in North-East Scotland. Outcome measures included; Prescription medicines use excluding vitamins and potential HDIs assessed using Natural Medicines Comprehensive Database. The survey was completed by 889 respondents (73% response rate). 45.3% (403) reported the use of at least one prescription medicine, excluding vitamins. Of those taking prescription medicines, 44.9% (181) also reported concurrent use of at least one HNP (Range 1–12). A total of 91 different prescription medicines were reported by respondents using HNPs. Of those taking prescription medicines, 44.9% (181) also reported concurrent use of at least one HNP (Range 1–12). Thirty-four herb-drug interactions were identified in 23 (12.7%) women with the potential to increase the risk of postpartum haemorrhage, alter maternal haemodynamics, and enhance maternal/fetal CNS depression. Almost all were rated as moderate (93.9%), one as a potentially major (ginger and nifedipine) and only one minor (ondansetron and chamomile). Almost half of pregnant women in this study were prescribed medicines excluding vitamins and minerals and almost half of these used HNPs. Potential moderate to severe HDIs were identified in an eighth of the study cohort. Healthcare professionals should be aware that the concurrent use of HNPs and prescription medicines during pregnancy is common and carries potential risks.